Document:

Exhibit 4.2

 

THE ISSUANCE OF THIS PROMISSORY NOTE, AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE (COLLECTIVELY, THE “SECURITIES”), HAVE NOT BEEN REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THE SECURITIES ARE BEING OFFERED PURSUANT TO CLAIMED EXEMPTIONS FROM REGISTRATION UNDER REGULATION D PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THE SECURITIES ARE “RESTRICTED SECURITIES” AND MAY NOT BE OFFERED OR RESOLD UNLESS THE SECURITIES ARE REGISTERED UNDER THE ACT, OR ELIGIBLE TO BE OFFERED OR SOLD PURSUANT TO AN APPLICABLE EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS.  THE COMPANY MAY REQUIRE THAT IT BE PROVIDED WITH OPINION OF COUNSEL OR OTHER SUCH INFORMATION AS IT MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH EXEMPTIONS ARE AVAILABLE. FURTHER, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE MADE EXCEPT IN COMPLIANCE WITH THE ACT.

 

ONPOINT MEDICAL DIAGNOSTICS, INC.

 

US $[                ]

 

This Promissory Note (the “Note”) is issued as of                              , 2010 by ONPOINT MEDICAL DIAGNOSTICS, INC., a Minnesota corporation (the “Company”), to                                                                                                                    (together with its permitted successors and assigns, the “Holder”) pursuant to exemptions from registration under the Securities Act of 1933, as amended.

 

ARTICLE I.

 

Section 1.01  Principal and Interest. The Company hereby promises to satisfy the principal sum of US $[                ] pursuant to the terms hereof and to pay interest to the Holder on such principal balance from the date hereof at the rate of ten percent (10%) per annum.

 

Section 1.02  Principal Satisfaction Dates.  One quarter of the original principal balance hereof shall be satisfied on each of June 30, 2012, December 31, 2012 and June 30, 2013.  Provided, however, against each such satisfaction shall be credited prior conversions of the principal balance hereof made by the Holder to the extent such conversion has not previously been applied to reduce the amount to be paid or satisfied under this note.  The then remaining outstanding principal balance hereof shall be satisfied on December 31, 2013.  Each such date is referred to herein as a “Principal Satisfaction Date”).  The Company shall satisfy the principal hereof by issuance to the Holder on each Principal Satisfaction Date of common stock of the Company.  Such issuance shall be based on the Conversion Price (as defined in Section 1.04) applicable on the Principal Satisfaction Date.

 

Section 1.03  Interest Payment Dates.  Accrued interest hereunder shall be paid on December 31, 2011 and on each of the Principal Satisfaction Dates.  Provided, however, that should the Holder have given the Company written notice at least ten business days prior to the date the interest is due to be paid, the Holder may receive shares of common stock for all or a portion of the interest due the Holder.  Such issuance shall be based on the Conversion Price applicable on the due date for the payment of interest.

 

Section 1.04  Conversion to Common Stock. The Holder shall have the option to convert all or a portion of the principal and accrued interest under this Note into common shares of the Company (the “Common Stock”) at any time prior to payment.  If the Holder has not optionally converted the principal

 

 

of this note, the Company shall issue to the Holder Common Stock as specified in Section 1.02.  The conversion price, in either case, shall be the lesser of (a) US$0.65 per share or (b) 65% of the volume weighted average of the Common Stock for the twenty trading dates preceding a conversion; however, the conversion price shall not be less than US$0.25 per share (the “Conversion Price”).  To optionally convert this Note, the Holder shall deliver written notice substantially in the form attached to this Note (the “Conversion Notice”), to the Company at its address as set forth herein. The date upon which the conversion shall be effective (the “Conversion Date”) shall be deemed to be the date set forth in the Conversion Notice or the date set forth in Section 1.02.  The Company shall not issue fractional shares upon a conversion.  If the application of the Conversion price shall contemplate issuance of less than a half share, such fractional share shall not be issued and no payment shall be made to the converting Holder and should such application result in the issuance of a half or greater fractional share, such fractional share shall be rounded up to the next full share.

 

Section 1.05 Reservation of Common Stock. The Company shall reserve and keep available out of its authorized shares of Common Stock a sufficient number of shares for the purpose of effecting the conversion of this Note.

 

ARTICLE II.

 

Section 2.01 No Prepayment.  This Note may not be prepaid by the Company without the express written consent of the Holder.

 

Section 2.02 Reverse Merger. In the event the Company has not completed a “reverse merger” with a corporation the equity interests of which are publicly held by March 31, 2011, the Holder may, in its sole discretion, demand payment of the principal balance of this Note, together with a penalty equal to twenty-five percent (25%) of the principal balance of the Note which amount is due and payable by the Company within 90 days of such demand.

 

ARTICLE III.

 

Section 3.01  Re-issuance of Note. Should the Holder elect to convert a part, but not all, of the unpaid principal amount then owing to the Holder under this Note, then the Company shall reissue a new Note in the same form as this Note to reflect the new principal amount and the accrued  unpaid interest which was not converted.

 

Section 3.02 Anti-dilution. In the event that the Company shall at any time subdivide the outstanding shares of Common Stock, or shall issue a stock dividend on the outstanding Common Stock merge with another corporation that effects a recapitalization of the Company, the Conversion Price in effect immediately prior to such subdivision, issuance of a dividend or merger shall be appropriately adjusted.

 

 

ARTICLE IV.

 

Section 4.01 Notices. Notices regarding this Note shall be sent to the parties at the following addresses, unless a party notifies the other parties, in writing, of a change of address:

 

If to the Holder, to:

 

 

	
If to the Company:
    	
 
    

 

Section 4.02 Governing Law. This Note shall be deemed to be made under and shall be construed in accordance with the laws of the State of Minnesota without giving effect to the principals of conflict of laws thereof.

 

Section 4.03 Severability. The invalidity of any of the provisions of this Note shall not invalidate or otherwise affect any of the other provisions of this Note, which shall remain in full force and effect.

 

Section 4.04 Entire Agreement and Amendments. This Note represents the entire agreement between the parties hereto with respect to the subject matter hereof and there are no representations, warranties or commitments, except as set forth herein. This Note may be amended only by an instrument in writing executed by the parties hereto.

 

Section 4.05.  No Waiver, Cumulative Remedies.  No failure to exercise and no delay in exercising, on the part any party, any right, remedy, power or privilege hereunder, shall operate as a waiver thereof, nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exhaustive of any rights, remedies, powers and privileges provided by law.

 

Section 4.06  Waiver of Trial by Jury.  To the extent permitted by applicable Law, each of the parties irrevocably waives all right of trial by jury in any action, proceeding or counterclaim arising out of or in connection with this Note or any matter arising hereunder.

 

Section .4.07  Legal Holidays.  In any case where the date on which any payment is due to any Holder shall not be a business day, then any such payment need not be made on such date, but may be made on the next succeeding business day with the same force and effect as if made on the date on which nominally due, and no interest shall accrue for the period from and after any such nominal date.

 

IN WITNESS WHEREOF, with the intent to be legally bound hereby, the Company as executed this Note as of the date first written above.

 

	
 
    	
ONPOINT MEDICAL   DIAGNOSTICS, INC.
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
a duly authorized officer
    

 

 

NOTICE OF CONVERSION

(To be executed by the Holder in order to convert the Note)

 

The undersigned hereby irrevocably elects to convert:

 

US$                                                             of the principal amount; AND

 

Please select one:

 

	
o
    	
 
    	
All of the accrued interest through the date   of conversion
    
	
o
    	
 
    	
None of the interest accrued through the date   of conversion
    
	
o
    	
 
    	
The following percentage of the interest   accrued through the date of conversion:              %
    

 

of the Holder’s Note issued by ONPOINT MEDICAL DIAGNOSTICS, INC.,(the “Company”) into Shares of Common Stock of the Company according to the conditions of conversion stated therein, as of the Conversion Date written below.

 

 

	
Conversion   Date:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Holder’s Signature
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Holder’s Name
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 Shares to be sent to :Exhibit 4.3

 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS (THE “BLUE SKY LAWS”), AND ARE SUBJECT TO A SUBSCRIPTION AGREEMENT AND LETTER OF INVESTMENT INTENT. THESE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF EITHER AN EFFECTIVE REGISTRATION UNDER THE 1933 ACT AND UNDER APPLICABLE BLUE SKY LAWS, OR AN OPINION OF COUNSEL FOR THE COMPANY THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION UNDER THE 1933 ACT AND UNDER APPLICABLE BLUE SKY LAWS.

 

ONPOINT MEDICAL DIAGNSOTICS, INC.

 

	
[    ]   (Issuance Date)
    	
 
    	
Shares   of Common Stock
    

 

WARRANT TO PURCHASE COMMON STOCK

 

This certifies that                                          (the “Holder”), is entitled to subscribe for and purchase during the period commencing on the date hereof and ending at 5:00 P.M., Minneapolis local time, on                       , 20    ,                                (                      ) shares (the “Shares”) of fully paid and nonassessable common stock (“Common Stock”) of OnPoint Medical Diagnostics, Inc., a Minnesota C corporation (the “Company”), at a purchase price per share equal to the Warrant Price (as defined below). The number of shares of Common Stock constituting the Shares and the Warrant Price shall be subject to adjustment as provided in Section 3 below.

 

1.                                       EXERCISE

 

(a)           Form. The purchase rights under this Warrant may be exercised by the Holder, in whole or in part, by completion of the Warrant Exercise form attached hereto as Exhibit A and the surrender of this Warrant at the principal office of the Company located at                           , and by the payment to the Company, by certified, cashier’s or other check acceptable to the Company, of an amount equal to the Warrant Price, multiplied by the number of Shares being purchased (the “Aggregate Warrant Price”).

 

(b)           Stock Certificates. In the event of any exercise of the rights to acquire Common Stock granted under this Warrant, certificates for the shares of Common Stock so purchased shall be delivered to the Holder within five (5) business days and, unless this Warrant has been fully exercised or has expired, a new Warrant representing the shares with respect to which this Warrant shall not have been exercised shall also be issued to the Holder within such time.

 

 

(c)           Warrant Price.

 

The purchase price for the shares of Common Stock to be issued upon exercise of this Warrant shall be $[    ] per share, subject to adjustment as provided in Section 3 herein (the “Warrant Price”).

 

2.                                       STOCK FULLY PAID: RESERVATION OF SHARES

 

The Company agrees that all securities that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be fully paid and nonassessable and free from all taxes, liens and charges with respect to the issuance thereof (excluding taxes based on the income of the Holder). The Company further agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved for issuance a sufficient number of shares of its Common Stock or other securities as would be required upon the full exercise of the rights represented by this Warrant.

 

3.                                       ADJUSTMENT

 

The kind of securities purchasable upon the exercise of this Warrant, the number of shares under this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the happening of certain events, as follows:

 

(a)           Reclassification. In case of any reclassification of the Common Stock, the Company shall execute a new Warrant that will provide that the Holder shall have the right to exercise such new Warrant and purchase upon such exercise, in lieu of the shares of Common Stock theretofore issuable upon exercise of this Warrant, the kind of securities receivable upon such reclassification by a holder of Common Stock immediately prior to such reclassification. Such new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided in this Section 3, and the provisions of this Section 3 shall similarly apply to any successive reclassifications. This adjustment shall be effective on the date of issuance of the security causing the adjustment.

 

(b)           Stock Splits. If the Company shall, at any time while this Warrant remains outstanding and unexercised, in whole or in part, effect stock splits and the like, then the Warrant Price and the number of shares issuable under this Warrant shall be equitably adjusted. This adjustment shall be effective on the effective date of the division or combination of shares.

 

4.                                       [CASHLESS EXERCISE

 

In lieu of exercising this Warrant for the Aggregate Warrant Price pursuant to Section 1, the Holder may exercise this Warrant by presentation and surrender of this Warrant to the Company at its principal executive offices with a Cashless Exercise Form in the form attached hereto as Exhibit B duly executed and indicating the number of Shares to be surrendered (a “Cashless Exercise”). In the event of a Cashless Exercise, the Holder shall exchange its warrant for that number of shares of Common Stock determined by multiplying the number of Shares by a fraction, the numerator of which shall be the amount by which the then current market price per share of Common Stock exceeds the then applicable Warrant Price, and the denominator of which shall be the then current market price per share of Common Stock. For purposes of any

 

2

 

computation under this Section 4, the then current market price per share of Common Stock at any date shall be deemed to be the fair market value of the shares of Common Stock on such date as determined in good faith by the Board of Directors of the Company.]

 

5.                                       FRACTIONAL SHARES

 

No fractional share of Common Stock will be issued in connection with any exercise hereof, but in lieu of a fractional share upon complete exercise hereof, the Holder may purchase a whole share at the then effective Common Stock price.

 

6.                                       MATERIAL EVENTS

 

(a)           If this Warrant is not exercised on or prior to to the first anniversary of the closing date of that certain Secured Convertible Debenture issued by OnPoint Medical Diagnostics, Inc.,  (a) all rights to which the Holder is entitled under this Warrant shall immediately terminate, (b) this Warrant shall be void and of no further force and effect, and (c) the Company shall have no further obligations to the Holder under this Warrant.

 

(b)           If this Warrant is not exercised on or prior to the closing date of a Public Offering (as defined below), then automatically upon consummation of such Public Offering: (a) all rights to which the Holder is entitled under this Warrant shall immediately terminate, (b) this Warrant shall be void and of no further force and effect, and (c) the Company shall have no further obligations to the Holder under this Warrant. The Company will notify the Holder of any proposed Public Offering at least fifteen (15) days prior to the expected closing of the Public Offering. As used herein, “Public Offering” means the sale of shares of Common Stock to the public in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended.

 

7.                                       SHAREHOLDER RIGHTS

 

The Holder shall not, solely by virtue hereof, be entitled to any rights of a shareholder of the Company. The Holder shall have all rights of a shareholder with respect to securities purchased upon exercise hereof at the time the Aggregate Warrant Price for such securities is delivered pursuant to Section 1 hereof and this Warrant is surrendered.

 

8.                                       TRANSFER

 

Neither this Warrant nor any rights hereunder may be assigned, conveyed or otherwise transferred without the prior written consent of the Company.

 

9.                                      GOVERNING LAW

 

This Warrant shall be governed by and construed in accordance with the laws of the State of Minnesota, without giving effect to the conflicts of law principles of that State or any other state.

 

3

 

10.                                 BINDING UPON SUCCESSORS AND ASSIGNS

 

Subject to, and unless otherwise provided in, this Warrant, each and all of the covenants, terms, provisions, and agreements contained herein shall be binding upon, and inure to the benefit of the permitted successors, executors, heirs, representatives, administrators and assigns of the parties hereto. The term “Holder” as used herein shall include, in addition to the initial Holder, any successors, endorsees, or other permitted assignees of such Holder and shall also include any other holder of this Warrant.

 

11.                                 SEVERABILITY

 

If any provision of this Warrant, or the application hereof, shall for any reason and to any extent, be invalid or unenforceable, the remainder of this Warrant and application of such provisions to other persons or circumstances shall be interpreted so as best to reasonably effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provisions of this Warrant with valid or enforceable provisions which will achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provisions.

 

12.                                 AMENDMENT

 

This Warrant may be amended or modified with the written consent of the Company and the Holder of this Warrant.

 

13.                                 NO WAIVER

 

The failure of any party to enforce any of the provisions hereof shall not be construed to be a waiver of the right of such party thereafter to enforce such provisions.

 

14.                                 NOTICES

 

Any and all notices, requests, consents, demands and other communications required or permitted to be given hereunder shall be in writing and shall be deemed effectively delivered (a) upon personal delivery to the party to be notified, (b) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, (c) one (1) day after deposit with a nationally recognized overnight courier, specifying next day priority delivery, with written verification of delivery, or (d) upon delivery by facsimile, with confirmation of delivery. All communications shall be sent to the respective parties as set forth below:

 

If to the Company, to:

 

OnPoint Medical Diagnostics, Inc.,

 

If to the Holder, to the address and facsimile number set forth in the Subscription Agreement pursuant to which this Warrant was issued, or as otherwise reflected in the Company’s records.

 

4

 

15.                                 NO ENDORSEMENT

 

The Holder understands that no federal or state securities administrator has made any finding or determination relating to the fairness of investment in the Company or purchase of the Common Stock hereunder and that no federal or state securities administrator has recommended or endorsed the offering of securities by the Company hereunder.

 

[Remainder of page intentionally left blank]

 

5

 

IN WITNESS WHEREOF, OnPoint Medical Diagnostics, Inc. has caused this Warrant to be signed by its duly authorized officer as of the date first set forth above.

 

	
 
    	
 
    	
 
    	
ONPOINT MEDICAL   DIAGNOSTICS, INC.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
 
    	
Title:
    

 

6

 

FORM OF WARRANT EXERCISE

(To be signed only on exercise of Warrant)

 

TO

 

The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise this Warrant for, and to purchase thereunder,                  shares of Common Stock of OnPoint Medical Diagnostics, Inc., a Minnesota C corporation, and herewith makes payment of $                    therefor, and requests that the certificates for such shares be issued in the name of, and delivered to                                     , whose address is                                                   .

 

	
Dated:
    	
 
    
	
 
    	
(Signature must conform to name of holder as
    
	
 
    	
specified on the face of the Warrant)
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
(Address)
    
	
 
    	
 
    
	
 
    	
Tax   Identification Number:
    	
 
    

 

 

[EXHIBIT B

 

CASHLESS WARRANT EXERCISE FORM

(To be signed only on exercise of Warrant)

 

The undersigned hereby irrevocably elects to exercise its Cashless Warrant Exercise rights, pursuant to Section 1 of the Warrant, with respect to shares of Common Stock of OnPoint Medical Diagnostics, Inc., a Minnesota C corporation, and requests that the certificates for such shares be issued in the name of, and delivered to whose address is                                                       . And if said number of shares shall not be all the shares exchangeable or purchasable under the within Warrant, a new Warrant is to be issued in the name of the undersigned for the balance remaining of the shares purchasable rounded up to the next higher number of shares.

 

	
Dated:
    	
 
    
	
 
    	
(Signature must conform to name of holder as
    
	
 
    	
specified on the face of the Warrant)
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
(Address)
    
	
 
    	
 
    
	
 
    	
Tax   Identification Number:
    	
 
    	
]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]